<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311411</url>
  </required_header>
  <id_info>
    <org_study_id>17223</org_study_id>
    <secondary_id>I8F-MC-GPHH</secondary_id>
    <nct_id>NCT04311411</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide in Overweight and Very Overweight Participants</brief_title>
  <official_title>Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure the effect of tirzepatide on food intake in&#xD;
      participants who are overweight or very overweight. The study will also use imaging to learn&#xD;
      more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on&#xD;
      appetite will also be studied. The study will last up to about four months and will include&#xD;
      up to 14 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">June 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Tirzepatide and placebo dosing are double-blind. Liraglutide dosing is open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Energy Intake (kilocalories per day)</measure>
    <time_frame>Baseline, Week 3</time_frame>
    <description>Energy intake (kcal/day) will be assessed by ad libitum food intake test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Blood Oxygenation Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation to Images of High-Fat Foods during the Fasting State in the Brain Reward Areas</measure>
    <time_frame>Baseline, Week 3</time_frame>
    <description>Change from Baseline in Blood Oxygenation Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation to Images of High-Fat Foods during the Fasting State in the Brain Reward Areas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting and Postprandial Appetite Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Week 3</time_frame>
    <description>The VAS scales will be analyzed as continuous variables on the 0-100 scale for individual components. Overall appetite score will be calculated as the average of the four individual scores (satiety + fullness + [100-prospective food consumption] + [100-hunger]/4). The higher overall appetite score indicates less appetite and the lower score indicates more appetite.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have stable body weight for the past 1 month prior to screening&#xD;
&#xD;
          -  Have a body mass index (BMI) between 27 to 50 kilograms per meter squared (kg/mÂ²),&#xD;
             inclusive at screening&#xD;
&#xD;
          -  Willing and agreeable to commit to the duration of the study and undergo study&#xD;
             procedures as instructed by the clinic staff&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have undergone or plan to undergo gastric bypass or bariatric surgery&#xD;
&#xD;
          -  Have claustrophobia or have ferromagnetic implants that can interfere with completion&#xD;
             of fMRI measurements&#xD;
&#xD;
          -  Have other medical conditions or medical history that make participation in the study&#xD;
             unsafe or which may interfere in the interpretation of the results of the study&#xD;
&#xD;
          -  Unwilling to comply with smoking and alcohol restrictions during the study&#xD;
&#xD;
          -  Have received prescription drugs or over the counter drugs that promote weight loss in&#xD;
             the past 6 months prior to screening&#xD;
&#xD;
          -  Have a diagnosis of type 2 diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>317-278-2389</phone>
    </contact>
    <investigator>
      <last_name>Robert V Considine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>225-763-2585</phone>
    </contact>
    <investigator>
      <last_name>Corby Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/3lm77tQ6Zi4YpYUnGE0fDr?conditionId=1wecF0AgauDdWnqHV7GJGP</url>
    <description>A Study of Tirzepatide in Overweight and Very Overweight Participants</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

